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arakat  syndrome  or HDR  synd
f kidney  disease  and  deafnes
índrome  hipoparathyroidism,  dea
índrome  de  Barakat  otra  asociació
ear Editor,
 a patient has kidney disease and deafness, we think on
lport syndrome, a widespread entity. However, this is not
ways the case. One of the recent issues of the journal
efrología included an excellent review of kidney disease in
e context of mitochondrial diseases and how nephrologists
ould suspect this diseases in a nephropathy (tubulopathy or
omerular injury, manifested by kidney failure and protein-
ria) which is accompanied by hearing loss or sensorineural
eafness.1 In this letter, we present a case of Barakat syn-
rome or hypoparathyroidism, deafness and renal dysplasia
DR) syndrome, another disease that should be included in
e differential diagnosis of kidney disease and hereditary
eafness.2,3
A 32-year-old patient was admitted to the obstetrics
epartment owing to oedema. She was 36 weeks pregnant and
e laboratory tests revealed a plasma creatinine at 1.4 mg/dl
d 6 grams of proteinuria in a 24-h urine collection. Medical
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me:  Another  association
ss  and  renal  displasia  o
e  sordera  y  nefropatía
istory included familial hypoparathyroidism in chronic
eatment with vitamin D and calcium carbonate, bilateral
nsorineural deafness and left kidney agenesis. With this his-
ry, in 2007, she was diagnosed with HDR syndrome. A genetic
udy demonstrated the presence of the c.431 mutation in the
ATA3 gene (gene for the transcription factor GATA3, located
 the short arm of chromosome 10). Both the patient and her
other were heterozygous for this mutation. The rest of the
mily (father, sister and maternal aunt) did not have any clini-
l manifestations of the syndrome; nevertheless, a molecular
netic study ruled out the presence of this mutation. Prior
 pregnancy, the patient had been examined in the urologyrnández Coronado A, Torres Aguilera E, Melero R, Tejedor A.
 de Barakat otra asociación de sordera y nefropatía. Nefrologia.
ndergone laboratory testing that showed mild kidney failure
ith a serum Cr of 1.3 mg/dl and proteinuria at 2.8 g/day.
Since she did not have HTN, the presence of pre-eclampsia
as ruled out, and she was diagnosed with worsening of renal
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Given the severe and persistent proteinuria with the pro-
gressive decline in kidney function, it was decided to perform
a Caesarean section, which proceeded without complications.
After birth, she was started on antiproteinuric treatment with
enalapril (10 mg/day). Currently (2 years after the birth), the
patient has stage-3 CKD, with plasma creatinine at 1.7 mg/dl,
glomerular ﬁltration rate estimated by the MDRD-4 equation
at 40 ml/min and albuminuria at 74 mg/day.
HDR syndrome or Barakat syndrome is a rare autosomal
dominant hereditary disease determined by a mutation in
the GATA3 gene, a gene located in the short arm of chro-
mosome 10.4 This gene is a transcription factor involved in
the embryonic development of the parathyroid glands, kid-
neys, inner ears, thymus and central nervous system. This
syndrome is characterised by the classic triad of familial pri-
mary  hypoparathyroidism, with the possible occurrence of
seizures, as a manifestation of hypocalcaemia, renal dysplasia
and various degrees of sensorineural deafness. Most cases are
bilateral.5
From a nephrology point of view, it may manifest with
hypoplasia, renal dysplasia or agenesis, pyelocalyceal defor-
mity, renal cysts, vesicoureteral reﬂux, renal tubular acidosis,
chronic kidney failure (sometimes requiring renal replace-
ment therapy), haematuria and various degrees of proteinuria.
Nephrotic syndrome, which is typically resistant to steroids,
may occur. The most common ﬁnding on kidney biopsy is focal
segmental glomerulosclerosis.6
Treatment is symptomatic and aimed at managing
or treating the clinical abnormalities associated with
hypoparathyroidism, deafness and kidney disease, essentially,
management of proteinuria.
Barakat syndrome is an uncommon cause of proteinuric
nephropathy that should be suspected in cases associated
with hypoparathyroidism and hereditary sensorineural deaf-
ness. Early diagnosis and treatment with renin–angiotensin
system blockers may help slow the progression of kidney fail-
ure and improve prognosis, which essentially depends on the
severity of kidney failure.
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